Christian BOREL


ORCID – ResearcherID


Liste des publications :

De Azevedo, J., Mourtada, J., Bour, C., Devignot, V., Schultz, P., Borel, C., Pencreach, E., Mellitzer, G., Gaiddon, C., & Jung, A. C. (2022). The EXTREME Regimen Associating Cetuximab and Cisplatin Favors Head and Neck Cancer Cell Death and Immunogenicity with the Induction of an Anti-Cancer Immune Response. Cells, 11(18), 2866.
Borel, C., Regnier-Gavier, O., Carinato, H., Guihard, S., Antoni, D., Demarchi, M., Sirlin, F., Exinger, D., Petit-Jean, E., Thiery, A., Bronner, G., Schultz, P., Flesch, H., Frasie, V., Prébay, D., Petit, T., Jung, A. C., Burgy, M., & Coliat, P. (2018). Interest to consider re-challenging by cetuximab and platinum containing regimen in recurrent Head and Neck Cancer. Oncotarget, 9(101), 37581–37588.
Jégu, J., Belot, A., Borel, C., Daubisse-Marliac, L., Trétarre, B., Ganry, O., Guizard, A.-V., Bara, S., Troussard, X., Bouvier, V., Woronoff, A.-S., Colonna, M., & Velten, M. (2015). Effect of previous history of cancer on survival of patients with a second cancer of the head and neck. Oral Oncology, 51(5), 457–463.
Jégu, J., Binder-Foucard, F., Borel, C., & Velten, M. (2013). Trends over three decades of the risk of second primary cancer among patients with head and neck cancer. Oral Oncology, 49(1), 9–14.
Le Tourneau, C., Jung, G.-M., Borel, C., Bronner, G., Flesch, H., & Velten, M. (2008). Prognostic factors of survival in head and neck cancer patients treated with surgery and postoperative radiation therapy. Acta Oto-Laryngologica, 128(6), 706–712.
Le Tourneau, C., Velten, M., Jung, G.-M., Bronner, G., Flesch, H., & Borel, C. (2005). Prognostic indicators for survival in head and neck squamous cell carcinomas: analysis of a series of 621 cases. Head & Neck, 27(9), 801–808.
Petit, T., Wilt, M., Velten, M., Millon, R., Rodier, J.-F., Borel, C., Mors, R., Haegelé, P., Eber, M., & Ghnassia, J.-P. (2004). Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. European Journal of Cancer (Oxford, England: 1990), 40(2), 205–211.
Cutuli, B., Borel, C., Dhermain, F., Magrini, S. M., Wasserman, T. H., Bogart, J. A., Provencio, M., de Lafontan, B., de la Rochefordiere, A., Cellai, E., Graic, Y., Kerbrat, P., Alzieu, C., Teissier, E., Dilhuydy, J. M., Mignotte, H., & Velten, M. (2001). Breast cancer occurred after treatment for Hodgkin’s disease: analysis of 133 cases. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology, 59(3), 247–255.
Petit, T., Georges, C., Jung, G. M., Borel, C., Bronner, G., Flesch, H., Massard, G., Velten, M., Haegele, P., & Schraub, S. (2001). Systematic esophageal endoscopy screening in patients previously treated for head and neck squamous-cell carcinoma. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 12(5), 643–646.
Cutuli, B., Dhermain, F., Borel, C., de Larochefordiere, A., Graic, Y., de Lafontan, B., Dilhyudy, J. M., Mignotte, H., Tessier, E., Tortochaux, J., N’Guyen, T., Bey, P., Le Mevel-Le Pourhiet, A., Velten, M., & Arriagada, R. (1997). Breast cancer in patients treated for Hodgkin’s disease: clinical and pathological analysis of 76 cases in 63 patients. European Journal of Cancer (Oxford, England: 1990), 33(14), 2315–2320.